目的 回顾性研究布地奈德气雾剂联合孟鲁司特钠咀嚼片,治疗儿童变异性哮喘的疗效与安全性.方法 随机选取本院2015年1月至2016年12月期间收治的咳嗽变异性哮喘患者120例,随机分为治疗组和对照组,每组60例,两组患者均给予对症的常规治疗.比如止咳化痰、抗感染、布地奈德气雾剂吸入等.治疗组在此基础上再给予口服孟鲁司特钠,比较两组患者的临床治疗效果,症状缓解时间等.结果 治疗组患者总有效率91.7％,显著高于对照组总有效率78.3％,差异有统计学意义(P＜0.05).血清免疫球蛋白水平IgE、嗜酸性粒细胞(EOS)计数治疗组在治疗后分别为(133.5±27.8)ng/L、(0.45±0.24)×109/L,显著优于对照组(172.9±34.2) ng/L、(0.73±0.31)×109/L,差异有统计学意义(P＜0.05);治疗组PEF升高值(95.5±11.6)L/min,明显优于对照组(79.3±13.1)L/min,差异有统计学意义(P＜0.05).在安全性方面,治疗组与对照组不良反应不存在明显差异(P＞0.05).结论 布地奈德气雾剂联合孟鲁司特钠用于治疗儿童咳嗽变异性哮喘有显著的临床效果,安全性较好,是治疗方案中选择性很高的治疗方法.%Objective To investigate the clinical effect and safety of singulair combined with budesonide in the treatment of cough variant asthma.Method 120 cases of cough variant asthma treated at our hospital from January,2015 to December,2016 were chosen and randomly divided into a treatment and a control group,60 for each group.Both groups took routine and symptomatic treatment,including relieving cough and reducing sputum,anti-infection,and inhaling budesonide.In addition,the treatment group orally took montelukast.The clinical effects and symptom-relieving times were compared between these two groups.Results The total efficacy was obviously higher in then observation group than in the control group (91.7％ vs.78.3％) (P ＜ 0.05).The level of IgE and the count of EOS were obviously better in the observation group than in the control group (P ＜ 0.05).There was no statistical difference in the incidence of adverse reactions between these two groups (P ＞ 0.05).Conclusion Montelukast sodium combined with budesonide for children with cough variant asthma is clinically effective and safe,so it is a good choice.
展开▼
